Sugi Predict

Sugi Predict / Compounds / SCHEMBL2497078

SCHEMBL2497078

SCHEMBL2497078

O=Cc1cc(Cl)cc(OC(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 3/20 0.49
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.34
▸ HPGD P15428 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ CCR6 P51684 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ ALDH1A3 P47895 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413618 0.86 DRD1 (0.57) DRD1KMT2AMEN1LMNAMAPT
SCHEMBL2800225 0.86 ALDH1A3 (0.38) DRD1KMT2AMAPTRAB9AHSD17B10
SCHEMBL3154943 0.86 DRD1 (0.35) DRD1KMT2AMAPTRAB9AHSD17B10
SCHEMBL3150404 0.83 DRD1 (0.33) DRD1HSD17B10
SCHEMBL16957301 0.81 LMNA (0.37) DRD1KMT2AMEN1LMNAMAPT
SCHEMBL13787900 0.81 MEN1 (0.34) DRD1KMT2AMEN1LMNAMAPT
SCHEMBL18002360 0.80 DRD1 (0.66) DRD1KMT2AMEN1LMNAMAPT
SCHEMBL18002399 0.80 DRD1 (0.57) DRD1KMT2AMEN1LMNAMAPT
SCHEMBL18003117 0.80 DRD1 (0.49) DRD1ALDH1A1HSD17B10AHR
SCHEMBL18002352 0.80 DRD1 (0.57) DRD1KMT2AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 — — US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 — — US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME ＵＢＥ株式会社 2023-05-19 — — WO disclosed
WO-2021230325-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE 宇部興産株式会社 2021-11-18 — — WO disclosed
JP-2011205986-A METHOD FOR PRODUCING OPTICALLY ACTIVE MANDELIC ACID DERIVATIVE NIPPON SHOKUBAI CO LTD 2011-10-20 — — JP disclosed
US-7820645-B2 Crystalline forms ASTRAZENECA AB (SE) 2010-10-26 — — US disclosed
US-7820645-B2 Crystalline forms ASTRAZENECA AB (SE) 2010-10-26 — — US disclosed
US-7803954-B2 Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system ASTRAZENECA AB (SE) 2010-09-28 — — US disclosed
US-7781424-B2 a time-release composition comprising antithrombins such as (2S)-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide, hydroxy propyl methyl cellulose and sodium stearyl fumarate as a lubricant; cardiovascular disorder ASTRAZENECA AB (SE) 2010-08-24 — — US disclosed
US-7763597-B2 Salts ASTRAZENECA AB (SE) 2010-07-27 — — US disclosed
EP-1401502-A1 PHARMACEUTICAL FORMULATION AstraZeneca AB (SE) 2004-03-31 — — EP disclosed
US-20040019033-A1 Mandelic acid derivatives and their use as throbin inhibitors ASTRAZENECA AB (SE) 2004-01-29 — — US disclosed
WO-2003101423-A1 IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
WO-2003101424-A1 MODIFIED RELEASE PHARMACEUTICAL FORMULATION ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
WO-2003101957-A1 NEW SALTS ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
WO-2003101956-A1 PHARMACEUTICAL COMBINATION ASTRAZENECA AB (SE) 2003-12-11 — — WO disclosed
EP-1347955-A1 NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS AstraZeneca AB (SE) 2003-10-01 — — EP disclosed
WO-2003018551-A1 NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2003-03-06 — — WO disclosed
WO-2003000293-A1 PHARMACEUTICAL FORMULATION ASTRAZENECA AB (SE) 2003-01-03 — — WO disclosed
WO-2002044145-A1 NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS ASTRAZENECA AB (SE) 2002-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019033-A1 Mandelic acid derivatives and their use as throbin inhibitors ADAMTS1, ADAMTS13, ADAMTS7 DRD1 1225/4885KMT2A 3693/4885MEN1 1523/4885
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 DRD1 109/4885KMT2A 359/4885MEN1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.